Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PlaTform Trial in Relapsed or Refractory Peripheral T-cell Lymphomas
NCT07018752Phase 2Recruiting
- Sponsor
- LYSARC
- Start
- Aug 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roginolisib, golcadomide in peripheral T-cell lymphoma (PTCL), sponsored by LYSARC. Started Aug 2025; status: recruiting.
02
Drugs
roginolisibgolcadomide
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07018752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018752.